Lumira Capital invests in Series E financing of Celtaxsys
Celtaxsys Inc, a U.S. clinical-stage developer of novel therapies for rare inflammatory diseases, has raised an undisclosed Series E financing. The round was led by U.S. private equity firm Invus Group and joined by several other investors, including Canadian life sciences venture capital firm Lumira Capital. The funds raised will support acceleration of the Phase 3 clinical and manufacturing preparatory activities for the company's lead candidate, acebilustat, an oral drug that aims to preserve lung function in cystic fibrosis. Founded in 2004, Celtaxsys has its headquarters in Atlanta, Georgia.
8 January 2018•4 mins read
